Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq

  • Company Update

Appointment of Odyssey Transfer and Trust Company as Transfer Agent for Turn Therapeutics

Shareholders of Turn Therapeutics:

We are pleased to announce that Odyssey Transfer and Trust Company has been appointed as the transfer agent for Turn Therapeutics. In this capacity, Odyssey will maintain and manage your shareholder account.   

You will soon receive an email from Odyssey containing an invitation and detailed instructions for accessing your account. Please ensure you review this communication promptly to stay informed about your holdings.   

Should you have any questions during the process, please do not hesitate to contact us Odyssey directly at [email protected]. Odyssey will work with the internal team as/if needs arise.   

Sincerely, 

Turn Therapeutics Team

Back to All News

Share

Related News

  • Westlake Village, CA
  • 1-818-564-4011

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Linkedin

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Linkedin

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Linkedin

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Linkedin

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.